Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation and Depletion: 2014-2024

Historic Depreciation and Depletion for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $15.5 million.

  • ImmunityBio's Depreciation and Depletion fell 12.82% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 13.84%. This contributed to the annual value of $15.5 million for FY2024, which is 6.06% down from last year.
  • Per ImmunityBio's latest filing, its Depreciation and Depletion stood at $15.5 million for FY2024, which was down 6.06% from $16.5 million recorded in FY2023.
  • ImmunityBio's Depreciation and Depletion's 5-year high stood at $16.5 million during FY2023, with a 5-year trough of $12.7 million in FY2020.
  • Over the past 3 years, ImmunityBio's median Depreciation and Depletion value was $16.3 million (recorded in 2022), while the average stood at $16.1 million.
  • In the last 5 years, ImmunityBio's Depreciation and Depletion spiked by 51.19% in 2020 and then declined by 6.06% in 2024.
  • ImmunityBio's Depreciation and Depletion (Yearly) stood at $12.7 million in 2020, then climbed by 11.81% to $14.2 million in 2021, then grew by 14.79% to $16.3 million in 2022, then increased by 1.23% to $16.5 million in 2023, then declined by 6.06% to $15.5 million in 2024.